« Previous Next » American Journal of Cardiology
Volume 96, Issue 11 , Pages 1589-1604 , 1 December 2005

The Editor’s Roundtable: Cyclooxygenase-2 Inhibitors and Cardiovascular Risk

Robert S. Bresalier, MD
- Professor and Chairman, Department of Gastrointestinal, Medicine and Nutrition, Birdie J and Lydia J Resoft Distinguished Professor in Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
- Dr. Bresalier is on the advisory board for Merck Research Laboratories, San Diego, California.
Vincent E. Friedewald Jr, MD
- Visiting Professor and Director, New Media Center, University of Notre Dame, Notre, Dame, Indiana
- Corresponding author: Tel: 574-631-7608; fax: 574-631-8209.
- Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
Robert E. Rakel, MD
- Professor, Department of Family and Community Medicine, Baylor College of Medicine, Houston, Texas
- Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
William C. Roberts, MD
- Medical Director, Baylor Heart and Vascular Institute, Baylor, University Medical Center, Dallas, Texas; Editor-in-Chief, The American Journal of Cardiology, and Dean, A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care, System, Dallas, Texas
- Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
Gary W. Williams, MD, PhD
- Chairman, Department of Medicine, Scripps Clinic, Medical Group; Vice President, Medicine Services and Academic Affairs Scripps Clinic Foundation, La Jolla, California.
- Dr. Williams receives honoraria for speaking and consulting for Pfizer, Inc., New York, New York. He is on the advisory board and conducts research protocols for Pfizer.